PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

Inclusion Criteria: * Patient must have malignancy with metastatic or recurrent diseases. * Patient must have a minimum of thirteen days period elapsed from any previous chemotherapy or radiotherapy and all treatment-related toxicities subsided. * Patient must have at least 2 courses of chemotherapy treatment left, and a minimum of 13 days between the administration of the last dose of the chemotherapy with PG2 and the start of the next course of chemotherapy. * Performance status is 0-2 by ECOG scale. * Patient's compliance and geographic proximity that allow adequate follow up. * Adequate bone marrow function before the chemotherapy * Adequate liver and renal function before the chemotherapy * Written informed consent from patients * Woman with childbearing potential should use contraception method through the whole PG2 treatment course. * After the previous course of chemotherapy, the nadir of WBC dropped between 1000 to 3000/ mm3 (for phase II only). Exclusion Criteria: * PG2 skin test is positive. * Active infection * Breast feeding * Prior radiotherapy more than 30% of the bone marrow involved. * Pregnant woman * Bone marrow transplantation or brain disease